TICKERNERD
Menu
PBYIPBYIHealthcare · Biotechnology

PBYI Stock Forecast: Puma Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$9.14
+0.22% on the day

The 1 Wall Street analysts covering Puma Biotechnology, Inc. hold a median 12-month price target of $6 — -34.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 12 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$470.8M
Ticker Nerd rank
92 / 100
Median analyst target
$6.00
Analysts covering
1
Revenue$56.5M+7.8% y/y
Operating income$7.6M
Net income$8.2M
Free cash flow$1.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.3%
1M
+3.5%
YTD
+53.6%
1Y
+104.5%
From 52W high
−5.7%
From 52W low
+110.6%
$4.34
$9.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PBYI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Puma Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Momentum
94
Value
94
Volatility
92
Issuance
85
Accruals
75
Size
54
Growth
31
Revisions
25

Quality (99): The business earns solid, repeatable profits on what it owns.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PBYI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBYI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$5.00$6.00$7.00$8.00$9.00$10.00Oct 25Jan 26Apr 26Jul 26PBYIHigh $6.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $6.00Median $6.00High $6.00

The green dot is the last close — the median target sits −34.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026TD CowenMaintainsHold$5.00 → $6.00
28 Feb 2025HC Wainwright & Co.ReiteratesBuy$7.00
28 Feb 2025HC Wainwright & Co.ReiteratesBuy—
23 Dec 2024HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
2 Aug 2024HC Wainwright & Co.ReiteratesBuy—
26 July 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
20 May 2024HC Wainwright & Co.ReiteratesBuy—
3 May 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.MaintainsBuy—
13 Feb 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2023HC Wainwright & Co.ReiteratesBuy—
4 Aug 2023HC Wainwright & Co.ReiteratesBuy—
5 June 2023HC Wainwright & Co.ReiteratesBuy—
5 May 2023HC Wainwright & Co.ReiteratesBuy—
6 Mar 2023HC Wainwright & Co.ReiteratesBuy—
31 Aug 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBYI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PBYI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Puma Biotechnology, Inc. returned +104.5% against +17.0% for the S&P 500, dividends included.

PBYI vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Oct 25Jan 26Apr 26Jul 26PBYIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PBYI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+22.2%
Analysts raising
0
Analysts cutting
0
Fundamentals

Puma Biotechnology, Inc. (PBYI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.9×

Cheaper than 41% of US stocks

Price / sales
2.0×

Cheaper than 52% of US stocks

Price / book
3.4×

Cheaper than 30% of US stocks

EV / EBITDA
9.5×

Cheaper than 40% of US stocks

Growth & margins
Revenue growth (YoY)
7.8%

Higher than 46% of US stocks

Earnings growth (YoY)
39.9%

Higher than 71% of US stocks

Gross margin
77.9%

Higher than 89% of US stocks

Operating margin
13.4%

Higher than 70% of US stocks

Net margin
11.6%

Higher than 73% of US stocks

Returns & dividend
Return on equity
22.0%

Higher than 83% of US stocks

Return on assets
9.8%

Higher than 92% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Puma Biotechnology, Inc. (PBYI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Puma Biotechnology, Inc. has a market value of $470.8M and an enterprise value of $381.7M.

  • Revenue in the twelve months to 30 June 2026: $231.2M. The latest quarter grew 7.8% year on year.

  • Net income over the same four quarters: $26.7M, a 11.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.52.

  • Free cash flow in the twelve months to 30 June 2026: $41.2M.

  • Shares outstanding: 51.1M.

  • Trailing P/E: 17.9×; forward P/E: 26.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Puma Biotechnology, Inc. employs 179 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

PBYI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PBYIPuma Biotechnology, Inc.$470.8M
92
SPRYARS Pharmaceuticals, Inc.$470.5M
13
RLMDRelmada Therapeutics, Inc.$474.1M
65
PRTAProthena Corp. Plc$480.7M
98
CAPRCapricor Therapeutics, Inc.$481.4M
9
EIKNEikon Therapeutics, Inc.$483.7M
1
CABACabaletta Bio, Inc.$445.1M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Puma Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBYI news & analysis

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

Business Wire · 9 Sept 2026neutral

Puma Biotechnology announced that CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026. The presentation was disclosed via a Business Wire statement from Los Angeles.

Why it matters — A PBYI watcher would note that the CEO's scheduled presentation gives investors an opportunity to hear a corporate overview from company leadership at a major investment conference.

Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

Seeking Alpha · 8 Sept 2026neutral

Puma Biotechnology's NERLYNX provides an established revenue stream that could support the development of alisertib into a potential second oncology franchise. The company currently has positive cash flows and a healthy balance sheet, while alisertib remains a speculative Phase 2 asset whose biomarker strategy may help identify responsive patients.

Why it matters — A PBYI watcher would care because NERLYNX's cash flow may fund the company's next potential oncology franchise in alisertib, though that candidate is still early-stage and speculative.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 3 Sept 2026neutral

Puma Biotechnology announced inducement awards granted in August 2026, reported as required under Nasdaq Listing Rule 5635(c)(4). The company disclosed the equity awards in a routine regulatory filing.

Why it matters — Observers of Puma Biotechnology would note this disclosure as it reflects the company's equity compensation practices and compliance with Nasdaq listing requirements, though it carries no direct impact on operations.

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Zacks Investment Research · 12 Aug 2026neutral

Zacks Investment Research published an article examining whether Puma Biotechnology (PBYI) is currently a great value stock. The piece explains that Zacks focuses on its Rank system, which emphasizes earnings estimates and estimate revisions, while also monitoring value, growth, and momentum trends to identify strong picks.

Why it matters — PBYI watchers would care because the article assesses the company's value-stock appeal using Zacks' earnings-estimate and trend-based methodology, which could inform how the stock is viewed by investors.

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Zacks Investment Research · 7 Aug 2026positive

Puma Biotechnology beat Q2 earnings and revenue estimates, raised its 2026 guidance, and noted rising Nerlynx sales along with upcoming milestones for its alisertib study.

Why it matters — PBYI watchers would care because the company exceeded expectations this quarter and raised its forward outlook, suggesting improved operational momentum.

FAQ

Frequently asked questions about PBYI stock

What is the PBYI stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Puma Biotechnology, Inc. have a median 12-month price target of $6, with estimates ranging from $6 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PBYI stock a buy right now?

Of the 1 analysts covering Puma Biotechnology, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Puma Biotechnology, Inc. 92 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PBYI?

As at 12 Sept 2026, Puma Biotechnology, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will PBYI stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies -34.4% from the last close, and Ticker Nerd's factor model ranks Puma Biotechnology, Inc. 92 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PBYI stock forecast for 2030?

No analyst covering Puma Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBYI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.

How has PBYI stock performed over the past year?

Puma Biotechnology, Inc. returned +104.5% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Puma Biotechnology, Inc. do?

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care.

What is the latest news on PBYI?

The most recent item we track (Business Wire, 9 Sept 2026): "Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference". Puma Biotechnology announced that CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026. The presentation was disclosed via a Business Wire statement from Los Angeles.

Company

About Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care. Its current portfolio centers on NERLYNX, an oral treatment based on neratinib used in specific HER2-positive breast cancer settings, along with alisertib, an investigational oncology candidate being studied across several tumor types. The company works through specialty pharmacy and distributor networks and maintains licensing and collaboration agreements that support the development, manufacture, and commercialization of its cancer-focused products. Puma Biotechnology serves patients and healthcare providers in the United States and select international markets, with an emphasis on targeted therapies for oncology. Based in Los Angeles, California, Puma Biotechnology plays a specialized role in the biotechnology market by concentrating on molecularly targeted cancer treatments and late-stage product commercialization.

CEO Mr. Alan H. Auerbach · 179 employees · United States · https://www.pumabiotechnology.com